12:00 AM
 | 
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PT003: Phase IIb data

A double-blind, U.S. Phase IIb trial in 159 patients with moderate to severe COPD showed that the 4 highest of 5 escalating doses of twice-daily PT003 administered via a metered dose inhaler significantly improved FEV1 AUC from 0-12 hours at day 7, the primary endpoint, vs. open-label tiotropium and...

Read the full 223 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >